Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors

Table 1

Patient’s characteristics.

	Group A ()	Group B ()
Age
Median (range) (years)	49 (28–73)	48 (28–73)
FIGO stage
Ia : Ib: IIa	4 : 78 : 27	7 : 67 : 27
Histology
Squamous : nonsquamous	86 : 23	101 : 0
Serum SCC antigen
Missing	2	4
Median (Range) (ng/mL)	1.40 (0.1–29.2)	1.50 (0.1–29.2)
Tumor size
≤4 cm : >4 cm	86 : 23	80 : 21
Depth of cervix invasion
≤1/2 : >1/2	26 : 83	27 : 74
Parametrial invasion
Negative : Positive	94 : 15	86 : 15
Resection margin involvement
Negative : Positive	85 : 24	86 : 15
Lymphovascular invasion
Negative : Positive	55 : 54	53 : 48
Pelvic lymph node involvement
Negative : Positive	76 : 33	71 : 30
Concurrent chemotherapy
No : Yes	29 : 80	31 : 70
External beam radiotherapy
No : Yes	0 : 109	8 : 93
Median (range) (Gy)	50.4 (25.2–54)	50.4 (5.4–54)
Brachytherapy
No : Yes	24 : 85	17 : 84
Median (range) (Gy)	21 (7–21)	21 (7–28)